InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,868.16
(
-1.36%
)
US TECH 100
19,863.20
(
-2.38%
)
Dow Jones
43,410.02
(
-0.78%
)
Brent Oil
70.83
(
-1.91%
)
Bitcoin
89,505.16
(
2.47%
)
Post# of 253617
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 839
Posts 120727
Boards Moderated 13
Alias Born 09/05/2002

DewDiligence

Member Level

Re: genisi post# 90856

Thursday, 06/24/2010 6:12:38 AM

Thursday, June 24, 2010 6:12:38 AM

Post# of 253617
FDA approves MRK’s Asamanex+Foradil combination for asthma:

http://www.reuters.com/article/idCNLDE65N0S320100624

The new product, called Dulera, will compete with GSK’s Advair and AZN’s Symbicort, which are also combinations of a corticosteroid and a LABA. However, Dulera’s approval may have come too late to accomplish much for MRK insofar as LABA’s are now considered unduly risky for the majority of asthma patients.


“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up